Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | $11.60 | $11.76 | $11.65 |
| Q2 2026 | 1 | $14.58 | $14.78 | $14.65 |
| Q3 2026 | 1 | $14.72 | $14.93 | $14.79 |
| Q4 2026 | 1 | $15.85 | $16.07 | $15.93 |
| Q1 2027 | 1 | $15.74 | $15.96 | $15.81 |
Dr. Reddy`s Laboratories Ltd. last posted its earnings results on Wednesday, January 21st, 2026. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by $0. The company had revenue of 87.27 B for the quarter and had revenue of 325.54 B for the year. Dr. Reddy`s Laboratories Ltd. has generated $68 earnings per share over the last year ($67.77 diluted earnings per share) and currently has a price-to-earnings ratio of 18.84. Dr. Reddy`s Laboratories Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 01/21/2026 | Q3 2026 | $0.16 | $14.53 | 14.37 | $83.34 B | $87.27 B |
| 10/24/2025 | Q2 2026 | $0.18 | $17.27 | 17.09 | $86.96 B | $88.05 B |
| 06/30/2025 | Q1 2026 | N/A | $17.04 | N/A | $86.94 B | $85.45 B |
| 06/06/2025 | Q4 2025 | N/A | $19.13 | N/A | $83.67 B | $85.06 B |
| 12/31/2024 | Q3 2025 | N/A | $16.96 | N/A | $81.30 B | $83.59 B |
| 09/30/2024 | Q2 2025 | N/A | $15.06 | N/A | $77.12 B | $80.16 B |
| 06/30/2024 | Q1 2025 | N/A | $16.69 | N/A | $72.98 B | $76.73 B |
| 06/12/2024 | Q4 2024 | N/A | $15.70 | N/A | $70.64 B | $70.83 B |
| 06/12/2024 | Q3 2024 | N/A | $16.56 | N/A | N/A | $72.15 B |
| 09/30/2023 | Q2 2024 | N/A | $17.79 | N/A | N/A | $832.20 M |
| 06/30/2023 | Q1 2024 | N/A | $84.38 | N/A | N/A | $67.38 B |
| 06/13/2023 | Q4 2023 | N/A | $57.60 | N/A | N/A | $765.60 M |
| 06/13/2023 | Q3 2023 | N/A | $75.09 | N/A | N/A | $67.70 B |
| 09/30/2022 | Q2 2023 | N/A | $67.40 | N/A | N/A | $790.11 M |
| 06/30/2022 | Q1 2023 | N/A | $71.56 | N/A | N/A | $52.15 B |
| 06/27/2022 | Q4 2022 | N/A | $5.28 | N/A | N/A | $722.59 M |
| 12/31/2021 | Q3 2022 | N/A | $42.58 | N/A | N/A | $53.20 B |
| 11/08/2021 | Q2 2022 | N/A | $59.80 | N/A | N/A | $777.86 M |
| 06/30/2021 | Q1 2022 | N/A | $34.44 | N/A | N/A | $49.19 B |
| 06/30/2021 | Q4 2021 | N/A | $33.38 | N/A | N/A | $648.67 M |
The conference call for Dr. Reddy`s Laboratories Ltd.'s latest earnings report can be listened to online.
The conference call transcript for Dr. Reddy`s Laboratories Ltd.'s latest earnings report can be read online.
Dr. Reddy`s Laboratories Ltd. (:RDY) has a recorded annual revenue of $325.54 B.
Dr. Reddy`s Laboratories Ltd. (:RDY) has a recorded net income of $56.54 B.Dr. Reddy`s Laboratories Ltd. has generated $67.85 earnings per share over the last four quarters.
Dr. Reddy`s Laboratories Ltd. (:RDY) has a price-to-earnings ratio of 18.84 and price/earnings-to-growth ratio is -5.45.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED